Devyser secures a major tender worth SEK 61.8 M in Udine, Italy
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a significant...
News | October 31, 2016
Devyser and JSI medical systems announce a joint solution for in-house processing of next-generation sequencing (NGS) data. The software platform provided by JSI has a newly developed plug-in that is compatible with all Devyser NGS products, including Devyser BRCA and Devyser CFTR. The solution is now available for all customers using the JSI sequence pilot platform, comprising more than 400 installations worldwide. In addition, Devyser will be able to offer installation of sequence pilot to its own customers that have in-house analysis capability.
This joint solution will simplify and streamline the diagnostic process for clinicians in hospitals and laboratories, enabling targeted therapies that benefit patients within oncology and hereditary diseases.
Ulf Klangby, CEO and co-founder of Devyser, says,
"Being able to offer our NGS kits to users of JSI’s software platform is a fantastic opportunity for us. JSI’s reputation of being at the forefront of bio-informatic platform development is completely aligned with our own philosophy of meeting the needs of the routine diagnostic lab, in this case those with full analytic capacity in-house."
Joachim Strub, CEO of JSI medical systems, comments,
"We are excited to enable a robust NGS solution together with Devyser. This will empower our customers and future users of the JSI platform to maintain full control of their analytical processes and results using the latest NGS technology."
